Misplaced Pages

Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.

This drug was developed by MedImmune/AstraZeneca.

References

1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
2. ClinicalTrial.gov for Oleclumab
3. Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibody stubs
• Monoclonal antibodies
• Drugs developed by AstraZeneca